Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Omi Parikh et al.|The Lancet Oncology|2019Cited by 643
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Núria Porta et al.|Cancer Discovery|2021Cited by 161
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou Lambros, Johann S. de Bono, George Seed et al.|Clinical Cancer Research|2018Cited by 110
Characterizing CDK12-Mutated Prostate CancersPasquale Rescigno, Johann S. de Bono, Bora Gürel et al.|Clinical Cancer Research|2020Cited by 100
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAdam Sharp, Johann S. de Bono, Jon Welti et al.|European Urology|2019Cited by 83